当前位置: X-MOL 学术Clin. Pharmacol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
MID3: Mission Impossible or Model-Informed Drug Discovery and Development? Point-Counterpoint Discussions on Key Challenges.
Clinical Pharmacology & Therapeutics ( IF 6.3 ) Pub Date : 2020-02-20 , DOI: 10.1002/cpt.1788
Sriram Krishnaswami 1 , Daren Austin 2 , Oscar Della Pasqua 3 , Marc R Gastonguay 4 , Jogarao Gobburu 5 , Piet H van der Graaf 6 , Daniele Ouellet 7 , Stacey Tannenbaum 8 , Sandra A G Visser 9
Affiliation  

MID3: Mission Impossible, or Model‐Informed, Drug Discovery and Development? At the 2019 ASCPT annual meeting, point‐counterpoint discussions were held on key challenges that limit, and future directions that enhance the adoption of MID3 across the drug discovery, development, regulatory and utilization continuum. We envision that the opportunities discussed, and lessons learned from having contrasting perspectives on issues that lack consensus may aid our discipline in more effectively implementing MID3 principles.

中文翻译:

MID3:不可能进行任务还是需要模型通知的药物开发?关于主要挑战的点对点讨论。

MID3:不可能执行任务或在模型通知下进行药物发现和开发?在2019年ASCPT年度会议上,就限制药物使用的关键挑战以及在药物发现,开发,监管和利用连续性领域中增强MID3应用的未来方向进行了点对点讨论。我们设想,讨论的机会和对缺乏共识的问题的不同观点所汲取的教训可能会帮助我们的学科更有效地实施MID3原则。
更新日期:2020-01-21
down
wechat
bug